Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands With BRCA1/2 Germline Mutations

NCT07039552 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07039552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07039552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands With BRCA1/2 Germline Mutations
Lead sponsor
Peking University Third Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2016
Completion date
December 30, 2035
Enrollment
10,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brca mutations, hereditary breast and ovarian cancer syndrome